What to watch with CYP2C19 and longevity?

CYP2C19 is a key drug-metabolizing enzyme (Phase I) that processes clopidogrel, proton pump inhibitors, and some antidepressants. A direct link to longevity is not scientifically established. Evidence is limited to mechanistic reasoning: variants (e.g., *2, *3, *17) alter enzyme activity, affecting drug efficacy and side effects. Over a lifetime, adverse drug reactions or altered metabolism of endogenous substrates (e.g., melatonin, arachidonic acid) could theoretically influence healthspan, but robust human studies with longevity as an endpoint are lacking. Consumer DNA tests often list CYP2C19 as a 'longevity gene,' which is misleading. Clinically, the gene is relevant in pharmacogenetics—for example, choosing clopidogrel or PPIs. For general life expectancy without medication, the impact is likely small. Beware of overinterpretation: a test result alone does not predict actual longevity. Evidence: mechanistic/unclear.